# A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

> **NCT06236880** · PHASE2 · RECRUITING · sponsor: **Gilgamesh Pharmaceuticals** · enrollment: 124 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** GM-2505

## Key facts

- **NCT ID:** NCT06236880
- **Lead sponsor:** Gilgamesh Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-31
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06236880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06236880, "A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06236880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*